Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 4, 2006American Journal of Respiratory and Critical Care Medicine

Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis

View Full Paper
Ask AI
Bookmark
Share

Authors

WBWilliam J. BurmanDenver Health Medical CenterSGStefan GoldbergCenters for Disease Control and PreventionJJJohn L. JohnsonRTI International

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Burman et al. (2006) studied this question.

synapsesocial.com/papers/6a716b1a35aa2c282ce2b8bbhttps://doi.org/10.1164/rccm.200603-360oc
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of Recoveries of <i>Mycobacterium tuberculosis</i> Using the Automated BACTEC MGIT 960 System, the BACTEC 460 TB System, and Lowenstein-Jensen Medium2000 · 137 citations
  2. 2Reassuring Safety Profile of Moxifloxacin2001 · 29 citations
  3. 3Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli1997 · 224 citations
  4. 4A Nested Case–Control Study on Treatment-related Risk Factors for Early Relapse of Tuberculosis2004 · 137 citations
  5. 5Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis2003 · 318 citations